Semantic Scholar uses AI to extract papers important to this topic.
Congenital hemophilia A, a relatively common and sometimes life-threatening bleeding disorder, is caused by inherited deficiency… Expand ACE910 is a recombinant humanized bispecific antibody that binds to activated factor IX and factor X and mimics the cofactor… Expand The development of inhibitors to factor VIII (FVIII) or factor IX (FIX) remains a major treatment complication encountered in the… Expand There are some issues in the current factor (F)VIII replacement therapy for severe hemophilia A. One is mental and physical… Expand For more than 3 decades, the scientific community has pursued gene correction of hemophilia, with the goal that an individual… Expand Background: ACE910, a humanized bispecific antibody to factor (F) IXa and FX mimicking the functions of FVIII, exerts tenase… Expand ACE910 is a humanized anti-factor IXa/X bispecific antibody mimicking the function of factor VIII (FVIII). We previously… Expand We previously reported that a humanized anti‐factor IXa/X bispecific antibody, hBS23, mimics the function of FVIII even in the… Expand BACKGROUND
We previously reported that a humanized anti-factor IXa/X bispecific antibody, hBS23, mimics the function of FVIII… Expand Background:
Although routine supplementation of exogenous factor VIII (FVIII) effectively prevents bleeding complications in… Expand